EGFR and non-small cell lung carcinoma: Although liquid biopsy has demonstrated a detection rate of up to 80 % in early-stage non-small cell lung cancer (NSCLC), the National Health Insurance (NHI) system in Taiwan currently reimburses EGFR mutations detected through tissue biopsy, rather than those identified via liquid biopsy.